Fidarestat

Fidarestat
Names
	IUPAC name (2S,4S)-6-fluoro-2',5'-dioxospiro[2,3-dihydrochromene-4,4'-imidazolidine]-2-carboxamide
	Other names (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide
Identifiers
CAS Number	105300-43-4 (unspecified) 136087-85-9; 105300-43-4 (unspecified);
ChEMBL	ChEMBL84446;
UNII	8SH8T1164U ;
CompTox Dashboard (EPA)	DTXSID4046654 ;
Properties
Chemical formula	C12H10FN3O4
Molar mass	279.22 g/mol
Melting point	290–300°
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Fidarestat (SNK-860) is an aldose reductase inhibitor used for treatment of diabetic neuropathy.

References

Aldose reductase inhibitor for treatment of diabetic complications. Prepn (stereo unspec): M. Kurono, et al., EP 193415; eidem, US 4740517 (1986, 1988 both to Sanwa). Prepn of isomers: T. Yamaguchi et al., Arzneim.-Forsch. 44, 344 (1994). Pharmacological profile: K. Mizuno et al. in Current Concepts of Aldose Reductase and Its Inhibitions, N. Sakamoto et al., Eds. (Elsevier, Amsterdam, 1990) pp 89-96. Configuration and crystal structure of complex with aldose reductase: M. Oka et al., J. Med. Chem. 43, 2479 (2000). Clinical efficacy in diabetic peripheral neuropathy: N. Hotta et al., Diabetes Care 24, 1776 (2001). Clinical suppression of sorbitol accumulation in erythrocytes of diabetic patients: T. Asano et al., J. Diabetes Complications 16, 133 (2002); eidem, ibid. 18, 336 (2004). Review of clinical development: N. Giannoukakis, Curr. Opin. Invest. Drugs 4, 1233-1239 (2003).

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.